



RECEIVED

JUL 20 2001

TECH CENTER 1600/2900

Subst. Form PTO-1449

Atty. Docket No.: 22727/04079

Serial No.: 09/747,521

APPLICANT'S INFORMATION  
DISCLOSURE STATEMENT

Applicant: Galloway, et al.

Filing Date: December 21, 2000

Group: 1645

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
KS	AA	5,591,631	January 7, 1997	Leppla, et al.	435	252.3	Feb. 12, 1993
LC	AB	5,677,274	October 14, 1997	Leppla, et al.	519	a	Jun. 25, 1993
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AK						
	AL						
	AM						
	AN						
	AO						

OTHER PRIOR ART

KS	AP	"Attenuated Nontoxinogenic and Nonencapsulated Recombinant <i>Bacillus anthracis</i> Spore Vaccines Protect Against Anthrax" by Cohen, et al., <u>Infection and Immunity</u> , August 2000, Vol. 68, No. 8, pp. 4549-4558.
LC	AQ	"Vaccination against Anthrax with Attenuated Recombinant Strains of <i>Bacillus anthracis</i> That Produce Protective Antigen" by Barnard, et al., <u>Infection and Immunity</u> , February 1999, Vol. 67, No. 2, pp. 562-567.
KH	AR	"Comparative Efficacy of <i>Bacillus anthracis</i> Live Spore Vaccine and Protective Antigen Vaccine against Anthrax in the Guinea Pig" by Little, et al., <u>Infection and Immunity</u> , May 1986, Vol. 52, No. 2, pp. 509-512.
KL	AS	"Nucleotide sequence and analysis of the lethal factor gene ( <i>lef</i> ) from <i>Bacillus anthracis</i> " by Bragg, et al., <u>Gene</u> , 81 (1989) 45-54.
	AT	
	AU	
	AV	
	AW	
	AX	
	AY	
	AZ	

Examiner:

*[Signature]*

Date Considered:

6/9/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.